To view this email as a web page, click here.
 
New hypertension drug gets FDA approval
Nebivolol and valsartan (Byvalson, Allergan) is a fixed-dose combination of a beta blocker and angiotensin II receptor blocker for hypertension
Read more
 
Risk of GI bleeding varies by NSAID type, dosage
The risk of gastrointestinal complications because of the use of nonsteroidal anti-inflammatory drugs (NSAIDs) varies by the specific drug and dosage.
Find out more
 
Prenatal vitamins: A review of the literature on benefits and risks of various nutrient supplements
Most pregnant women take a daily prenatal vitamin, but advising the patient can be difficult because so many different formulations are available.
Read more
 
5 things to know about the new HIV treatment
Here are the top 5 things to know about Genvoya, a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide for patients with HIV-1 infection.
Read more
 
New 340B drug rule sets drugmaker fines
After considerations of the comments received on the 340B Drug Discount Program rule, HHS is delaying the effective date of the January 5, 2017, final rule, to July 1, 2018.
Read more
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.